Skip to main content

Donovan Chin, Ph.D.

Vice President, Computational Drug Discovery

Donovan leads FogPharma’s Computational Drug Discovery, leveraging cutting edge technologies in AI/ML and physics-based methods to tackle HeliconTM drug-discovery problems. He is an experienced leader in initiating and building world-class computational/AI/ML teams and platforms at Arrakis, Novartis, Biogen and Transform Pharmaceuticals acquired by J&J. Donovan is an early pioneer in computational drug discovery, integrating disparate drug-discovery systems, and cloud supercomputing, with a track record of incorporating AI/ML and physics-based methods to open up new frontiers in drug discovery.   Donovan has 25+ years industry experience spanning multiple disease areas with small molecules, proteins, RNA and peptides. He is a co-inventor of branaplam, a small molecule targeting RNA in Spinal Muscular Atrophy  (SMA) disease. Donovan holds a B.S. in Chemistry from University of Florida, a Ph.D. in Polymer Science and Engineering from University of Massachusetts-Lowell, and was a postdoctoral fellow in Chemistry at Harvard University with George M. Whitesides.